Thinly traded nano cap VIVUS (VVUS +4.3%) is up, albeit on very light volume, on the heels of its announcement that
that its marketing application in Europe seeking approval of Qsymia
(phentermine and topiramate extended-release) has been accepted for
review by lead member state Sweden. If approved, the weight loss med
will be authorized for sale throughout the EU as early as H2 2020 under
its decentralized procedure.
The FDA approved it in July 2012.
https://seekingalpha.com/news/3504235-vivus-4-percent-advancement-qsymia-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.